MedPHA

Shanghai MedPha Biopharmaceutical is a clinical-stage biotechnology company based in Shanghai, China, dedicated to the discovery and development of innovative small molecule therapeutics for oncology and autoimmune diseases. The company focuses on high-selectivity kinase inhibitors designed to address unmet medical needs with improved safety and efficacy profiles. Its lead program, MP-001, is a potent and selective Bruton's tyrosine kinase (BTK) inhibitor currently undergoing Phase 1/2 clinical evaluation for the treatment of B-cell malignancies. Additionally, MedPha is advancing MP-002, a selective JAK1 inhibitor, into clinical trials for inflammatory conditions such as rheumatoid arthritis. Leveraging its internal R&D capabilities and strategic location in the Zhangjiang Hi-Tech Park, the company aims to build a robust pipeline of next-generation targeted therapies.